Method for reducing intraocular pressure in the mammalian eye by administration of guanylate cyclase inhibitors
First Claim
1. A method of treating animals of the mammalian species, including humans, for the purpose of reducing intraocular pressure in the eye of the mammal, comprising the step of administering to the mammal a pharmaceutical composition which comprises as its active ingredient one or more compounds having guanylate cyclase inhibition activity, wherein said compound having guanylate cyclase inhibition activity is selected from the group consisting of methylene blue, butylated hydroxyanisole, N-methyl hydroxylamine and pharmaceutically acceptable salts thereof.
1 Assignment
0 Petitions
Accused Products
Abstract
Pharmaceutical compositions and a method are disclosed for treating glaucoma and/or ocular hypertension in the mammalian eye by administering to the mammalian eye the pharmaceutical composition of the invention which contains as the active ingredient one or more compounds having guanylate cyclase inhibition activity. Examples of guanylate cyclase inhibitors utilized in the pharmaceutical composition and method of treatment are methylene blue, butylated hydroxyanisole and N-methylhydroxylamine.
-
Citations
5 Claims
- 1. A method of treating animals of the mammalian species, including humans, for the purpose of reducing intraocular pressure in the eye of the mammal, comprising the step of administering to the mammal a pharmaceutical composition which comprises as its active ingredient one or more compounds having guanylate cyclase inhibition activity, wherein said compound having guanylate cyclase inhibition activity is selected from the group consisting of methylene blue, butylated hydroxyanisole, N-methyl hydroxylamine and pharmaceutically acceptable salts thereof.
- 4. A method for providing neuroprotective effect to the eye of a mammal which comprises the step of administering to the mammal a pharmaceutical composition which comprises as its active ingredient one or more compounds having guanylate cyclase inhibition activity, wherein said compound having guanylate cyclase activity is selected from the group consisting of methylene blue, butylated hydroxyanisole, N-methyl hydroxyl amine and pharmaceutically acceptable salts thereof.
Specification